Testing sleep apnea treatment before heart rhythm ablation in atrial fibrillation
Tests screening and treating sleep apnea in adults with atrial fibrillation considered for ablation.
Plain-language title generated from the registry record
Registry title: Value of Screening and Treatment of SAHS in the Management of AF Ablation Candidates
Key facts
- Where
- Madrid, SpainSee the site
Where in Spain
- Hospital Clínico San CarlosMadrid, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hospital San Carlos, Madrid
- Trial code
- NCT04606693
- Record updated
- 15 September 2025
- Original description
The present prospective cohort study (not randomized) analyses the value of screening and treatment of SAHS in the management of patients with AF refractory to antiarrhythmics drugs, potentially candidates for ablation.Read full original descriptionShow less
Value of Screening and Treatment of Sleep Apnea-Hypopnea Syndrome in the Management of Atrial Fibrillation Ablation Candidates
The present prospective cohort study (not randomized) analyses the value of screening and treatment of SAHS in the management of patients with AF refractory to antiarrhythmics drugs, potentially candidates for ablation.
Patients at low risk of suffering from SAHS will follow conventional management of their AF, according to the usual criteria of the Arrhythmia Unit. Patients with high or intermediate risk of SAHS, will undergo respiratory polygraphy. If the result is positive, they will be treated as standard for this syndrome and their heart rate will be monitored for 3 months. After this, the patient's arrhythmic load will be reevaluated differentiating patients into two groups, those that must be ablated from those that have improved their condition and the clinical criteria is no longer ablation but follow-up.
Inclusion: Patients with paroxysmal or persistent atrial fibrillation; Recurrent atrial fibrillation despite treatment with at least one class I or III antiarrhythmic; No previous diagnosis of apnea-hypopnea syndrome.
Exclusion: Patients <18 years; Pregnant women; Doubts about the patient's ability to perform a home respiratory polygraphy; Doubts about the patient's ability to acquire rhythm records with the Kardia system (smartphone required); Unavailability for follow-up at our center for at least 1 year.